Specifically, our data argue that a lack of IL-17 axis activation leads to decreased downstream production of inflammatory mediators known to drive NAFLD; including, CXCL10, CCL2, CCL22, and TNF. This evidence concerns the gene CCL22 and metabolic dysfunction-associated steatotic liver disease.